– Plans for Phase 3 Program Presented at National Kidney Foundation’s Annual Spring Clinical Meeting – Research Triangle Park, N.C., April 7, 2022 – Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range of best-in-class therapies for patients with end stage kidney disease (ESKD), today announced plans …